Dianthus Therapeutics, a clinical-stage biotechnology firm, has initiated a Phase 2 clinical trial for
DNTH103, an investigational drug for
generalized Myasthenia Gravis (gMG). The FDA has cleared the IND application for the drug, and the trial's primary focus is on safety and tolerability, with secondary endpoints involving activity and quality of life assessments. The study will involve up to 60 patients and is expected to deliver initial results in the second half of 2025.
DNTH103 is a monoclonal antibody designed to inhibit the active form of the
C1s protein, a key component in the classical complement pathway, which is implicated in gMG. The drug is enhanced with technology that extends its half-life, allowing for less frequent subcutaneous injections. It is anticipated to be a more convenient and safer alternative to existing treatments.
Simrat Randhawa, the Chief Medical Officer of Dianthus Therapeutics, expressed excitement about advancing DNTH103 into the Phase 2 study following positive Phase 1 data. Mazen M. Dimachkie, a neurology professor, highlighted the importance of addressing the complement classical pathway in gMG and the potential of DNTH103 to meet patient needs.
DNTH103's development is part of Dianthus's broader strategy to build a neuromuscular franchise. The company plans to expand its trials to include other neuromuscular conditions such as
Multifocal Motor Neuropathy and
Chronic Inflammatory Demyelinating Polyneuropathy in 2024.
Dianthus Therapeutics is based in New York City and Waltham, Massachusetts, and is committed to developing next-generation antibody complement therapeutics to treat severe
autoimmune diseases. The company's experienced team is focused on creating transformative medicines for individuals with severe autoimmune and inflammatory conditions.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
